Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYMPHONY HD: Enarodustat vs darbepoetin alfa in anemic CKD patients on hemodialysis
jRCT2080223881Phase 3Completed
- Sponsor
- Japan Tobacco
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of enarodustat in anaemia and chronic kidney disease (CKD) (2 arms), sponsored by Japan Tobacco. Primary endpoints: Efficacy in maintaining hemoglobin levels and Safety and tolerability over 24 weeks. Started Apr 2018; status: completed.
02
Drugs
enarodustat
03
Conditions
anaemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2080223881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223881.